Jylamvo is a drug owned by Shorla Pharma Ltd. It is protected by 2 US drug patents filed in 2023 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 28, 2035. Details of Jylamvo's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11129833 | Methotrexate formulation |
Oct, 2035
(10 years from now) | Active |
| US11771701 | Methotrexate formulation |
Oct, 2034
(9 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Jylamvo's patents.
Latest Legal Activities on Jylamvo's Patents
Given below is the list of recent legal activities going on the following patents of Jylamvo.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Email Notification Critical | 22 Jan, 2024 | US11129833 |
| Change in Power of Attorney (May Include Associate POA) Critical | 22 Jan, 2024 | US11129833 |
| Change in Power of Attorney (May Include Associate POA) Critical | 22 Jan, 2024 | US11771701 |
| Email Notification Critical | 22 Jan, 2024 | US11771701 |
| Patent eGrant Notification | 03 Oct, 2023 | US11771701 |
| Patent Issue Date Used in PTA Calculation Critical | 03 Oct, 2023 | US11771701 |
| Recordation of Patent eGrant | 03 Oct, 2023 | US11771701 |
| Mail Patent eGrant Notification | 03 Oct, 2023 | US11771701 |
| Recordation of Patent Grant Mailed Critical | 03 Oct, 2023 | US11771701 |
| Email Notification Critical | 03 Oct, 2023 | US11771701 |
US patents provide insights into the exclusivity only within the United States, but Jylamvo is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Jylamvo's family patents as well as insights into ongoing legal events on those patents.
Jylamvo's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Jylamvo's generic launch date based on the expiry of its last outstanding patent is estimated to be Oct 28, 2035 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Jylamvo Generics:
There are no approved generic versions for Jylamvo as of now.
Alternative Brands for Jylamvo
Jylamvo which is used for treating severe psoriasis in adults., has several other brand drugs using the same active ingredient (Methotrexate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
About Jylamvo
Jylamvo is a drug owned by Shorla Pharma Ltd. It is used for treating severe psoriasis in adults. Jylamvo uses Methotrexate as an active ingredient. Jylamvo was launched by Shorla in 2022.
Approval Date:
Jylamvo was approved by FDA for market use on 29 November, 2022.
Active Ingredient:
Jylamvo uses Methotrexate as the active ingredient. Check out other Drugs and Companies using Methotrexate ingredient
Treatment:
Jylamvo is used for treating severe psoriasis in adults.
Dosage:
Jylamvo is available in solution form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 2MG/ML | SOLUTION | Prescription | ORAL |